Abstract:
The present invention concerns substances which act as selective ligands of nuclear receptors of the PPAR beta/delta subtype and which can be used for the treatment of PPAR beta/delta-mediated diseases. The substances of this invention act as inhibitors of PPAR beta/delta receptors.